DeCure for Vertebral hypersegmentation and orofacial anomalies
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for vertebral hypersegmentation and orofacial anomalies — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleVertebral hypersegmentation and orofacial anomalies maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for vertebral hypersegmentation and orofacial anomalies is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
growth differentiation factor 11 (GDF11) — GDF11 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet flcdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5JHW · 2.35 Å · ligand CITRATE ANION (FLC). Experimental structure, not a prediction.
What the evidence adds up to
The two abstracts that mention vertebral segmentation defects do not name any drug. The 2012 review states that severe segmentation defects of the vertebrae in humans result from disruption of the genetic mechanism that regulates somite formation, specifically the cyclical expression of genes in the Notch, Wnt, and fibroblast growth factor (FGF) signalling pathways. The 2009 review of congenital scoliosis and kyphosis notes that congenital vertebral anomalies have the potential to progress rapidly and can cause serious complications such as neurologic deficit, but it offers no pharmacological intervention.
The 2000 paper on Goldenhar syndrome (oculo-auriculo-vertebral syndrome) proposes that the condition may result from ectodermal nondisjunction early in development, possibly involving a molecular mechanism with cell adhesion molecules. It does not test or propose any drug. No abstract reports a clinical trial, a survival rate, a response rate, or any patient sample treated with a drug for vertebral hypersegmentation or orofacial anomalies.
What is missing is any clinical trial, any tested drug, any patient stratification, and any funding for a repurposing study in this group of conditions. The basic biology points to Notch, Wnt, and FGF pathways as potential targets, but no abstract here moves from that observation to a treatment.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Spine · 2009 · 128 citations
The Natural History of Congenital Scoliosis and Kyphosis
AbstractIn Brief Study Design. Review article. Objective. To discuss natural history of congenital scoliosis and kyphosis. Summary of Background Data. Review of previously published literature on natural history of congenital spine deformities. Methods. Medline and google search for congenital scoliosis, kyphosis, and kyphoscoliosis, congenital spine anomalies, deformities, and pathologies, and congenital vertebral anomalies, deformities, and pathologies was performed. Results. Congenital vertebral anomalies have potential to progress and careful assessment and monitoring is essential and early intervention may be desirable. Conclusion. Congenital vertebral anomalies invariably result from disturbed asymmetric growth and can have serious consequences. Congenital vertebral deformities have the potential to progress rapidly and significantly. One must be aware of this potential for progression, less they miss the opportunity to intervene and modify the growth of these anomalies to prevent deformity. This is particularly true, to avoid serious and disastrous complications such as neurologic deficit.
Scoliosis and segmentation defects of the vertebrae
AbstractAbstract The vertebral column derives from somites, which are transient paired segments of mesoderm that surround the neural tube in the early embryo. Somites are formed by a genetic mechanism that is regulated by cyclical expression of genes in the Notch, Wnt, and fibroblast growth factor (FGF) signaling pathways. These oscillators together with signaling gradients within the presomitic mesoderm help to set somitic boundaries and rostral–caudal polarity that are essential for the precise patterning of the vertebral column. Disruption of this mechanism has been identified as the cause of severe segmentation defects of the vertebrae in humans. These segmentation defects are part of a spectrum of spinal disorders affecting the skeletal elements and musculature of the spine, resulting in curvatures such as scoliosis, kyphosis, and lordosis. While the etiology of most disorders with spinal curvatures is still unknown, genetic and developmental studies of somitogenesis and patterning of the axial skeleton and musculature are yielding insights into the causes of these diseases. WIREs Dev Biol 2012, 1:401–423. doi: 10.1002/wdev.34 This article is categorized under: Early Embryonic Development > Development to the Basic Body Plan Vertebrate Organogenesis > Musculoskeletal and Vascular Birth Defects > Organ Anomalies
Journal of Craniofacial Surgery · 2000 · 38 citations
A Theory on the Embryogenesis of Oculo-Auriculo-Vertebral (Goldenhar) Syndrome
AbstractOculo-auriculo-vertebral (OAV) syndrome is made up of anomalies, mainly of first and second branchial arch derivatives. Characteristic features include structural malformations of the external and middle ears, face, and jaw. It has been previously suggested that hemorrhage involving the first and second branchial arches causes hypoplasia and malformation of the face and auricle, but this theory cannot explain the multisystemic and protean manifestations of this disease. The theory set forth describes the cutaneous, facial, vertebral, and systemic anomalies in the OAV spectrum as a result of ectodermal nondisjunction early in development with subsequent mesodermal tethering. A subgroup of OAV may therefore be a disorder of ectodermal nondisjunction involving the otic placode similar to the spectrum of diseases such as occult spinal dysraphism that is associated with the same mechanism in the embryonic neuraxis. This would imply a molecular mechanism involving cell adhesion molecules that unify the two disease processes and explain the multisystem anomalies of the OAV syndrome.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
